Skip Navigation
Find a Doctor


Photo of Dr. Robert Brodsky

Robert Alan Brodsky, MD

Director, Division of Hematology
Professor of Medicine
Appointment Phone


Main Location

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

View All Locations
Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-0773 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »


  • Director, Division of Hematology
  • Professor of Medicine
  • Professor of Oncology

Centers & Institutes

  • Sidney Kimmel Comprehensive Cancer Center


Aplastic Anemia, Bone Marrow Failure, Hematologic Malignancies, Hematology, Medical Oncology, Myelodysplastic Syndrome, Paraoxysysmal Nocturnal Hemoglobinuria

Research Interests

high-dose cyclophosphamide, aplastic anemia, paroxysmal nocturnal hemoglobinuria




  • English


1994 American Society of Hematology

2001 International Society of Experimental Hematology

2004 Fellow - American College of Physicians

Clinical Trial Keywords

  • aplastic anemia, high-dose cyclophosphamide

Additional Resources

Additional Resources +
  • Education +


    • Hahnemann University Hospital ( Philadelphia PA ) (1989)


    • Vanderbilt University School of Medicine/Internal Medicine ( Nashville TN ) (1991)


    • The Johns Hopkins Hospital/Oncology ( Baltimore MD ) (1997)
    • National Institutes of Health - Credentialing Services Section/Hematology ( Bethesda MD ) (1994)


    • Hematology, American Board of Internal Medicine (2006)
  • Research & Publications +

    Research Summary

    Dr. Brodsky's major clinical research involves the study of aplastic anemia, PNH and other bone marrow failure disorders. His research shows that immunoablative doses of cyclophosphamide, without bone marrow transplantation, can lead to durable complete remissions in severe aplastic anemia. The reason high-dose cyclophosphamide is able to ablate the effector cells without destroying hematopoietic stem cells is that the earliest stem cells (but not lymphocytes) contain high levels of aldehyde dehydrogenase conferring resistance to the cytoxic properties of cyclophosphamide. Dr. Brodsky and his colleagues in neurology and rheumatology are applying this approach in other severe autoimmune disorders including, scleroderma, myasthenia gravis, multiple sclerosis and autoimmune hematologic disorders.

    Dr. Brodsky's major laboratory interests relate to the study of normal and abnormal hematopoiesis. Specifically his lab studies PIG-A gene mutations in aplastic anemia. His group has developed a novel diagnostic assay for PNH based on the pore forming toxin (aeromonas hydrophila).

    Selected Publications

    1. Brodsky, R.A.; Hu, R. PIG-A mutations in paroxysmal nocturnal hemoglobinuria and in normal hematopoiesis. Leuk Lymphoma. 2006 Jul;47(7):1215-1221.
    2. Brodsky, R.A.; Jones, R.J. Aplastic Anemia. In: Rose, N.R.; Mackay, I.R., editors. 4th ed, The Autoimmune Diseases. Philadelphia, PA: Elsevier; 2006.
    3. Hillmen, P.; Young, N.S.; Schubert, J.; Brodsky, R.A.; Socie, G.; Muus, P.; Roth, A.; Szer, J.; Elebute, M.O.; Nakamura, R.; Browne, P.; Risitano, A.M.; Hill, A.; Schrezenmeier, H.; Fu, C.L.; Maciejewski, J.; Rollins, S.A.; Mojcik, C.F.; Rother, R.P.; Luzzatto, L. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006 Sep 21;355(12):1233-1243.
    4. Huff, C.A.; Fuchs, E.J.; Smith, B.D.; Blackford, A.; Garrett-Mayer, E.; Brodsky, R.A.; Flinn, I.W.; Ambinder, R.F.; Borrello, I.M.; Matsui, W.H.; Vogelsang, G.B.; Griffin, C.A.; Luznik, L.; Jones, R.J. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant. 2006 Apr;12(4):414-421.
    5. Kuo, G.P.; Brodsky, R.A.; Kim, H.S. Catheter-directed thrombolysis and thrombectomy for the Budd-Chiari syndrome in paroxysmal nocturnal hemoglobinuria in three patients. J Vasc Interv Radiol. 2006 Feb;17(2 Pt 1):383-387.
    6. Maroney, S.A.; Cunningham, A.C.; Ferrel, J.; Hu, R.; Haberichter, S.; Mansbach, C.M.; Brodsky, R.A.; Dietzen, D.J.; Mast, A.E. A GPI-anchored co-receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression. J Thromb Haemost. 2006 May;4(5):1114-1124.
    7. Matsui, W.H.; Brodsky, R.A.; Smith, B.D.; Borowitz, M.J.; Jones, R.J. Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia. 2006 Mar;20(3):458-462.
    8. Bolanos-Meade, J.; Garrett-Mayer, E.; Luznik, L.; Anders, V.; Webb, J.; Fuchs, E.J.; Huff, C.A.; Matsui, W.; Borrello, I.M.; Brodsky, R.; Kasamon, Y.L.; Swinnen, L.J.; Flinn, I.W.; Ambinder, R.F.; Jones, R.J.; Hess, A.D.; Vogelsang, G.B. Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biol Blood Marrow Transplant. 2007 Oct;13(10):1185-1191.
    9. Hillmen, P.; Muus, P.; Duhrsen, U.; Risitano, A.M.; Schubert, J.; Luzzatto, L.; Schrezenmeier, H.; Szer, J.; Brodsky, R.A.; Hill, A.; Socie, G.; Bessler, M.; Rollins, S.A.; Bell, L.; Rother, R.P.; Young, N.S. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007 Dec 1;110(12):4123-4128.
    10. Rother, R.P.; Rollins, S.A.; Mojcik, C.F.; Brodsky, R.A.; Bell, L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007 Nov;25(11):1256-1264.
    11. Savage, W.J.; DeRusso, P.A.; Resar, L.M.; Chen, A.R.; Higman, M.A.; Loeb, D.M.; Jones, R.J.; Brodsky, R.A. Treatment of hepatitis-associated aplastic anemia with high-dose cyclophosphamide. Pediatr Blood Cancer. 2007 Dec;49(7):947-951.
    12. Brodsky, R.A. Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of complement-related hemolytic anemia. Ann Intern Med. 2008 Apr 15;148(8):587-595.
    13. Brodsky, R.A. Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria. Blood Rev. 2008 Mar;22(2):65-74.
    14. Brodsky, R.A.; Jones, R.J. Intensive immunosuppression with high dose cyclophosphamide but without stem cell rescue for severe autoimmunity: Advantages and disadvantages. Autoimmunity. 2008 Oct 28:1.
    15. Brodsky, R.A.; Luznik, L.; Bolanos-Meade, J.; Leffell, M.S.; Jones, R.J.; Fuchs, E.J. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant. 2008 Oct;42(8):523-527.
    16. Brodsky, R.A.; Young, N.S.; Antonioli, E.; Risitano, A.M.; Schrezenmeier, H.; Schubert, J.; Gaya, A.; Coyle, L.; de Castro, C.; Fu, C.L.; Maciejewski, J.P.; Bessler, M.; Kroon, H.A.; Rother, R.P.; Hillmen, P. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008 Feb 15;111(4):1840-1847.
    17. Chen, G.; Ye, Z.; Yu, X.; Zou, J.; Mali, P.; Brodsky, R.A.; Cheng, L. Trophoblast differentiation defect in human embryonic stem cells lacking PIG-A and GPI-anchored cell-surface proteins. Cell Stem Cell. 2008 Apr 10;2(4):345-355.
    18. Drachman, D.B.; Adams, R.N.; Hu, R.; Jones, R.J.; Brodsky, R.A. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann N Y Acad Sci. 2008;1132:305-314.
    19. Krishnan, C.; Kaplin, A.I.; Brodsky, R.A.; Drachman, D.B.; Jones, R.J.; Pham, D.L.; Richert, N.D.; Pardo, C.A.; Yousem, D.M.; Hammond, E.; Quigg, M.; Trecker, C.; McArthur, J.C.; Nath, A.; Greenberg, B.M.; Calabresi, P.A.; Kerr, D.A. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol. 2008 Aug;65(8):1044-1051.
    20. Luznik, L.; O'Donnell, P.V.; Symons, H.J.; Chen, A.R.; Leffell, M.S.; Zahurak, M.; Gooley, T.A.; Piantadosi, S.; Kaup, M.; Ambinder, R.F.; Huff, C.A.; Matsui, W.; Bolanos-Meade, J.; Borrello, I.; Powell, J.D.; Harrington, E.; Warnock, S.; Flowers, M.; Brodsky, R.A.; Sandmaier, B.M.; Storb, R.F.; Jones, R.J.; Fuchs, E.J. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008 Jun;14(6):641-650.
    21. Tehlirian, C.V.; Hummers, L.K.; White, B.; Brodsky, R.A.; Wigley, F.M. High-dose cyclophosphamide without stem cell rescue in scleroderma. Annals of the rheumatic diseases. 2008 Jun;67(6):775-781.
    22. Warlick, E.D.; O'Donnell, P.V.; Borowitz, M.; Grupka, N.; Decloe, L.; Garrett-Mayer, E.; Borrello, I.; Brodsky, R.; Fuchs, E.; Huff, C.A.; Luznik, L.; Matsui, W.; Ambinder, R.; Jones, R.J.; Douglas Smith, B. Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res. 2008 Sep;32(9):1439-1447.
    23. Bolanos-Meade, J.; Brodsky, R.A. Blood and marrow transplantation for sickle cell disease: overcoming barriers to success. Curr Opin Oncol. 2009 Mar;21(2):158-161.
    24. Bolanos-Meade, J.; Luznik, L.; Muth, M.; Matsui, W.H.; Huff, C.A.; Smith, B.D.; Levy, M.Y.; Kasamon, Y.L.; Swinnen, L.J.; Powell, J.D.; Brodsky, R.A.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transplant. 2009 Mar;43(6):477-480.
    25. Brodsky, R.A. How I treat paroxysmal nocturnal hemoglobinuria. Blood. 2009 Jun 25;113(26):6522-6527.
    26. Emadi, A.; Brodsky, R.A. Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2009 Oct;84(10):699-701.
    27. Emadi, A.; Jones, R.J.; Brodsky, R.A. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009 Nov;6(11):638-647.
    28. Fuchs, E.J.; Luznik, L.; Bolanos-Meade, J.; Miller, C.B.; Brodsky, R.A.; Ambinder, R.F.; Jones,R.J. Successful pregnancy and childbirth after reduced-intensity conditioning and partially HLA-mismatched BMT. Bone Marrow Transplant. 2009 Jun;43(12):969-970.
    29. Hu, R.; Mukhina, G.L.; Lee, S.H.; Jones, R.J.; Englund, P.T.; Brown, P.; Sharkis, S.J.; Buckley, J.T.; Brodsky, R.A. Silencing of genes required for glycosylphosphatidylinositol anchor biosynthesis in Burkitt lymphoma. Exp Hematol. 2009 Apr;37(4):423-434 e422.
    30. Kasamon, Y.L.; Luznik, L.; Leffell, M.S.; Kowalski, J.; Tsai, H.L.; Bolanos-Meade, J.; Morris, L.E.; Crilley, P.A.; O'Donnell, P.V.; Rossiter, N.; Huff, C.A.; Brodsky, R.A.; Matsui, W.H.; Swinnen, L.J.; Borrello, I.; Powell, J.D.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. Nonmyeloablative HLA-Haploidentical BMT with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome. Biol Blood Marrow Transplant. 2009 Nov 16.
    31. Parker, C.J.; Brodsky, R.A.; Levine, J.E. Treatment versus transplant for challenging hematologic disorders. Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):72-78.
    32. Savage, W.J.; Barber, J.P.; Mukhina, G.L.; Hu, R.; Chen, G.; Matsui, W.; Thoburn, C.; Hess, A.D.; Cheng, L.; Jones, R.J.; Brodsky, R.A. Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNH. Exp Hematol. 2009 Jan;37(1):42-51.
    33. Singer, A.L.; Locke, J.E.; Stewart, Z.A.; Lonze, B.E.; Hamilton, J.P.; Scudiere, J.R.; Anders, R.A.; Rother, R.P.; Brodsky, R.A.; Cameron, A.M. Successful liver transplantation for Budd-Chiari syndrome in a patient with paroxysmal nocturnal hemoglobinuria treated with the anti-complement antibody eculizumab. Liver Transpl. 2009 May;15(5):540-543.
    34. Brodsky, R.A. High-dose cyclophosphamide for autoimmunity and alloimmunity. Immunol Res. 2010 Jul;47(1-3):179-184
    35. Brodsky, R.A.; Chen, A.R.; Dorr, D.; Fuchs, E.J.; Huff, C.A.; Luznik, L.; Smith, B.D.; Matsui, W.H.; Goodman, S.N.; Ambinder, R.F.; Jones, R.J. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood. 2010 Mar 18;115(11):2136-2141.
    36. Dezern, A.E.; Luznik, L.; Fuchs, E.J.; Jones, R.J.; Brodsky, R.A. Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia. Bone Marrow Transplant. 2010 Sep 13.
    37. Kasamon, Y.L.; Jones, R.J.; Brodsky, R.A.; Fuchs, E.J.; Matsui, W.; Luznik, L.; Powell, J.D.; Blackford, A.L.; Goodrich, A.; Gocke, C.D.; Abrams, R.A.; Ambinder, R.F.; Flinn, I.W. Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma. Ann Oncol. 2010 Jun;21(6):1203-1210.
    38. Kasamon, Y.L.; Luznik, L.; Leffell, M.S.; Kowalski, J.; Tsai, H.L.; Bolanos-Meade, J.; Morris, L.E.; Crilley, P.A.; O'Donnell, P.V.; Rossiter, N.; Huff, C.A.; Brodsky, R.A.; Matsui, W.H.; Swinnen, L.J.; Borrello, I.; Powell, J.D.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010 Apr;16(4):482-489.
    39. Luznik, L.; Bolanos-Meade, J.; Zahurak, M.; Chen, A.R.; Smith, B.D.; Brodsky, R.; Huff, C.A.; Borrello, I.; Matsui, W.; Powell, J.D.; Kasamon, Y.; Goodman, S.N.; Hess, A.; Levitsky, H.I.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010 Apr 22;115(16):3224-3230.
    40. Mali, P.; Chou, B.K.; Yen, J.; Ye, Z.; Zou, J.; Dowey, S.; Brodsky, R.A.; Ohm, J.E.; Yu, W.; Baylin, S.B.; Yusa, K.; Bradley, A.; Meyers, D.J.; Mukherjee, C.; Cole, P.A.; Cheng, L. Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells. 2010 Apr;28(4):713-720.
    41. Petri, M.; Brodsky, R.A.; Jones, R.J.; Gladstone, D.; Fillius, M.; Magder, L.S. High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial. Arthritis Rheum. 2010 May;62(5):1487-1493.
    42. Smith, B.D.; Jones, R.J.; Cho, E.; Kowalski, J.; Karp, J.E.; Gore, S.D.; Vala, M.; Meade, B.; Baker, S.D.; Zhao, M.; Piantadosi, S.; Zhang, Z.; Blumenthal, G.; Warlick, E.D.; Brodsky, R.A.; Murgo, A.; Rudek, M.A.; Matsui, W.H. Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. Leuk Res. 2011 Jan;35(1):87-94.
    43. Brodsky RA, Sensenbrenner LL, Jones RJ. Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. Blood. 1996; 87(2):491-4. PubMed PMID: 8555470.
    44. Brodsky RA, Vala MS, Barber JP, Medof ME, Jones RJ. Resistance to apoptosis caused by PIG-A gene mutations in paroxysmal nocturnal hemoglobinuria. Proceedings of the National Academy of Sciences. 1997;94(5):8756-60. PubMed PMID: 9238050; PubMed Central PMCID: PMC23114.
    45. Brodsky RA, Petri M, Smith BD, Seifter EJ, Spivak JL, Styler M, Dang CV, Brodsky I, Jones RJ. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Annals of Internal Medicine. 1998;129(12):1031-5. PubMed PMID: 9867758.
    46. Brodsky RA, Mukhina GL, Nelson KL, Lawrence TS, Jones RJ, Buckley JT. Resistance of paroxysmal nocturnal hemoglobinuria cells to the glycosylphosphatidylinositol-binding toxin aerolysin. Blood. 1999; 93(5):1749-56. PubMed PMID: 10029605.
    47. Brodsky RA, Mukhina GL, Li S, Nelson KL, Chiurazzi PL, Buckley J, Borowitz MJ. Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin. American Journal of Clinical Pathology. 2000; 114(3):459-66. PubMed PMID: 10989647.
    48. Chen R, Eshleman JR, Brodsky RA, Medof ME. Glycosylphosphatidylinositol-anchored protein deficiency as a marker of mutator phenotypes in cancer. Cancer Research. 2001; 61(2):654-8. PubMed PMID: 11212264.
    49. Brodsky RA, Sensenbrenner LL, Smith BD, Dorr D, Seaman PJ, Lee SM, Karp JE, Brodsky I, Jones RJ. Durable treatment-free remission following high-dose cyclophosphamide for previously untreated severe aplastic anemia. Annals of Internal Medicine. 2001; 135(7):477-83. PubMed PMID: 11578150.
    50. Mukhina GL, Buckley JT, Barber JP, Jones RJ, Brodsky RA. Multilineage Glycosylphosphatidylinositol anchor-deficient haematopoiesis in untreated aplastic anaemia. British Journal of Haematology. 2001; 115(2):476-82. PubMed PMID: 11703352.
    51. Moyo VM, Smith BD, Brodsky I, Crilley P, Jones RJ, Brodsky RA. High-dose cyclophosphamide for refractrory autoimmune hemolytic anemia. Blood. 2002; 100(2):704-6. PubMed PMID: 12091370.
    52. Petri M, Jones RJ, Brodsky RA. High dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis and Rheumatism. 2003; 48(1):166-73. PubMed PMID: 12528116.
    53. Nagajothi N, Matsui WH, Mukhina GL, Brodsky RA. Enhanced cytotoxicity of rituximab following genetic and biochemical disruption of glycosylphosphatidylinositol anchored proteins. Leukemia and Lymphoma. 2004; 45(4):795-9. PubMed PMID: 15160958.
    54. Brodsky RA, Chen A, Brodsky I, Jones RJ. High-dose cyclophosphamide as salvage therapy for severe aplastic anemia. Experimental Hematology. 2004;32(5):435-40. PubMed PMID: 15145211.
    55. Moyo VM, Mukhina GL, Garrett ES, Brodsky RA. Natural history of paroxysmal nocturnal hemoglobinuria using modern diagnostic assays. British Journal of Haematology. 2004; 126(1):133-8. PubMed PMID: 15198744.
    56. Hu R, Mukhina GL, Piantadosi S, Barber JP, Jones RJ, Brodsky RA. PIG-A mutations in normal hematopoiesis. Blood. 2005; 105(10):3848-54. PubMed PMID: 15687243; PubMed Central PMCID: PMC1895084.
    57. Brodsky RA, Jones RJ. Aplastic Anemia. Lancet. 2005; 365(9471):1647-56. Review. PubMed PMID: 15885298.
    58. Armanios M, Chen JL, Chang YPC, Brodsky RA, Hawkins A, Griffin CA, Eshleman JR, Cohen AR, Chakravarti A, Hamosh A, Greider CW. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Procedings of the National Academy of the Sciences. 2005; 102(44):15960-4. PubMed PMID: 16247010; PubMed Central PMCID: PMC1276104.
    59. Matsui WM, Brodsky RA, Smith BD, Borowitz MJ, Jones RJ. Quantitative analysis of bone marrow cd34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia. 2006; 20(3):458-62. PubMed PMID: 16437138.
    60. Hillmen MB, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, Roth A, Szer J Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu C, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. New England Journal of Medicine. 2006; 355(12):1233-43. PubMed PMID: 16990386.
    61. Hillmen P, Muus P, Duhrsen DM, Risitano AM, Schubert J, Luzzatto, L, Schrezenmeier, H, Szer, J, Brodsky, RA, Hill, A, Socie, G, Bessler, M, Rollins, SA, Bell, L, Rother, RP, Young, NS. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110(12):4123-8. PubMed PMID: 17702897.
    62. Brodsky RA. Narrative review: Paroxysmal Nocturnal Hemobloginuria: the physiology of complement-related hemolytic anemia. Annals of Internal Medicine. 2008; 148(8):587-95. Review. PubMed PMID: 18413620.
    63. Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, Valls AG, Coyle L, de Castro C, Fu CL, Maciejewski JP, Bessler M, Kroon HA, Rother RP, Hillmen P. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008; 111(4):1840-7. PubMed PMID: 18055865.
    64. Chen G, Ye Z, Yu X, Zou J, Mali P, Brodsky RA, Cheng L. Trophoblast differentiation defect in human embryonic stem cells lacking PIG-A and GPI-anchored cell-surface proteins. Cell Stem Cell. 2008; 2(4):345-55. PubMed PMID: 18397754; PubMed Central PMCID: PMC2442565.
  • Academic Affiliations & Courses +
  • Activities & Honors +


    1988 Chairman''s Invitational Honors Program

    1989 Samuel Levit, M.D. Award - Outstanding Clinical and Humanitarianism in the care of Medical Patients

    1989 James P. Fullin Memorial Award - Outstanding Clinical and Academic Performance in Hematology/Oncology

    1989 Academic Honors: Oncology

    1989 Academic Distinctions: Medicine, Neurology

    1994 American Society of Hematology Travel Award

    1996 1st Prize, Johns Hopkins Oncology Center Fellow Research Day

    1996 American Society of Hematology Travel Award

    1997 Thomas E. Sandefur, Jr. Fellow in Stem Cell Research

    1998 Junior Faculty Scholar, American Society of Hematology

    2000 Leukemia and Lymphoma Society of America Scholar
  • Videos & Media +


    Getting off the Ground

    Alvin Myerbergs generosity takes HiCy studies at Hopkins to the next level.

    Johns Hopkins Medicine: Aplastic Anemia

    A Remarkable Journey

    Throughout its history, Johns Hopkins has always been willing to head into unchartered territory. Fueled by philanthropy, we have gone places farther than envisioned and more rewarding than we could have possibly imagined. Along the way, we may face challenges. No matter what, we never give up. We believe in the potential of the next generation and in the wisdom of experience. From the microscopic level of the cell to the outer limits of space, every day we transform our world and you make this remarkable journey possible.

  • Upcoming Events +
  • Contact & Locations +


    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    401 N. Broadway
    Baltimore, MD 21231
    Phone: 410-502-2546
    Appointment Phone: 410-955-8964
    Fax: 410-955-0185
    Location Map


    • Medicine - Hematology

Is This You? Edit Profile


© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer